Navigation Links
Celsion Corporation Announces $9.83 Million Registered Direct Offering
Date:5/31/2013

LAWRENCEVILLE, N.J., May 31, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) (the "Company") today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $9.83 million of the Company's common stock in an at-the-market registered direct offering led by a dedicated health care fund.

The Company entered into definitive purchase agreements with these investors pursuant to which the Company agreed to sell an aggregate of 6,264,492 shares of its common stock at a per share price of $1.57.  The shares were priced at-the-market with no discount to the previous day's closing bid price.  In addition, there were no warrants issued as part of this financing transaction.  The closing of the offering is expected to take place on or about June 4, 2013, subject to the satisfaction of customary closing conditions.

The estimated net proceeds to the Company from the offering are expected to be approximately $9.1 million.  With the net proceeds from this offering, the Company projects to have an unaudited cash and investment balance of approximately $50 million.  The Company intends to use the net proceeds from this offering for general corporate purposes.

H.C. Wainwright & Co., LLC  acted as exclusive placement agent in connection with the offering.

A shelf registration statement (File No. 333-183286) relating to the shares issued in the offering has been filed with and declared effective by the Securities and Exchange Commission (the "SEC").  A prospectus supplement relating to the offering will be filed by the Company with the SEC.  Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at http://www.sec.gov, from request at H.C. Wainwrig
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
2. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
3. Celsion Corporation Provides Business Update
4. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
5. Celsion Corporation Announces $15 Million Registered Direct Offering
6. Sigma-Aldrich Corporation Presentations At Three Upcoming Conferences To Be Webcast Live
7. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
8. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
9. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
10. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
11. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
(Date:7/1/2015)... , July 1, 2015 InferMed ... technology will ... evidence-based clinical s olutions suite   ... and medical information products and services, announced today the acquisition ... decision support (CDS) technology company. InferMed,s Arezzo technology ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty ... the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty ... this course combines students from both universities and is taught on both continents. ...
(Date:6/30/2015)... -- Today, Americord Registry, one of the fastest growing cord blood ... partner at Kirkland & Ellis LLP, as the newest member ... http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about Andrew ... Smithmyer , CEO of Americord. "He brings a wealth of ... Americord,s growth and vision." Andrew Horne ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... patients with cutaneous T-cell lymphoma on schedule for completion ... June 29 Yaupon Therapeutics, a privately held specialty ... a pivotal Phase 2 clinical trial for Clearazide for ... stages 1-2a). The study, which is being conducted ...
... , PRINCETON, N.J., June 29 DOR ... (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced ... Center, Seattle, Washington, published a paper this morning in ... that DOR,s lead product orBec(R) (oral beclomethasone dipropionate or ...
... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today reported that YM,s subsidiary, CIMYM BioSciences ... between the companies in a cooperative effort. CIMYM ...
Cached Biology Technology:Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 3DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 4DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 5DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 6YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 2YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 3YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 4
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... was recently discovered in the cloud-forests of Peru. The large ... a bit like one, except its closest relatives are spiny ... yet strange looking, with long dense fur, a broad blocky ... on the crown, nape and shoulders add to its distinctive ...
... Washington University School of Medicine in St. Louis, living ... Then, because of the unusual meal, the cells were ... mice. , Developed in the laboratories of Samuel ... nanoparticles could soon allow researchers and physicians to directly ...
... to develop a quick, simple and cheap immune-system test for ... in the poorest countries get appropriate treatment to extend their ... , The work is part of an $8.6 million international ... London and funded by the Bill and Melinda Gates Foundation. ...
Cached Biology News:Scientists discover new species of distinctive cloud-forest rodent 2Nanoparticles can track cells deep within living organisms 2Nanoparticles can track cells deep within living organisms 3Cornell researcher helping develop quick, cheap HIV/AIDS test 2
SAPK/JNK Antibody...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Component in MasterPure™ Purification Kits...
Biology Products: